CA2953987A1 - Therapie antitumorale par ciblage de ews-fli1 - Google Patents

Therapie antitumorale par ciblage de ews-fli1 Download PDF

Info

Publication number
CA2953987A1
CA2953987A1 CA2953987A CA2953987A CA2953987A1 CA 2953987 A1 CA2953987 A1 CA 2953987A1 CA 2953987 A CA2953987 A CA 2953987A CA 2953987 A CA2953987 A CA 2953987A CA 2953987 A1 CA2953987 A1 CA 2953987A1
Authority
CA
Canada
Prior art keywords
ews
group
hydrogen
halogen
fli1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2953987A
Other languages
English (en)
Inventor
Jeffrey A. Toretsky
Aykut Ueren
Milton Lang Brown
Yali Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of CA2953987A1 publication Critical patent/CA2953987A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2953987A 2006-12-29 2007-12-28 Therapie antitumorale par ciblage de ews-fli1 Abandoned CA2953987A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87785606P 2006-12-29 2006-12-29
US60/877856 2006-12-29
CA2711003A CA2711003C (fr) 2006-12-29 2007-12-28 Therapie antitumorale par ciblage de ews-fli1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2711003A Division CA2711003C (fr) 2006-12-29 2007-12-28 Therapie antitumorale par ciblage de ews-fli1

Publications (1)

Publication Number Publication Date
CA2953987A1 true CA2953987A1 (fr) 2008-07-10

Family

ID=39589226

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2711003A Active CA2711003C (fr) 2006-12-29 2007-12-28 Therapie antitumorale par ciblage de ews-fli1
CA2953987A Abandoned CA2953987A1 (fr) 2006-12-29 2007-12-28 Therapie antitumorale par ciblage de ews-fli1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2711003A Active CA2711003C (fr) 2006-12-29 2007-12-28 Therapie antitumorale par ciblage de ews-fli1

Country Status (4)

Country Link
EP (2) EP2687206B1 (fr)
AU (1) AU2007341977B2 (fr)
CA (2) CA2711003C (fr)
WO (1) WO2008083326A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
US8710068B2 (en) * 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
NZ723971A (en) * 2012-04-12 2018-01-26 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
KR20160065986A (ko) 2013-10-24 2016-06-09 조지타운 유니버시티 암 치료용 방법 및 조성물
CN107108580B (zh) * 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
JP6864379B2 (ja) 2016-03-31 2021-04-28 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インドール類似体及びその使用
US10159660B2 (en) 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
CN108186630B (zh) * 2017-12-18 2020-07-31 温州医科大学 靛红类似物在制备抗肿瘤药物中的应用
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
EP4058593A4 (fr) * 2019-11-12 2023-11-15 Foundation Medicine, Inc. Méthodes de détection d'un gène de fusion codant pour un néo-antigène
CN110950928A (zh) * 2019-12-16 2020-04-03 武汉大学 尤文肉瘤靶向诊断用多肽
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1155572C (zh) * 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) * 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
JP4584987B2 (ja) * 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
WO2006117414A1 (fr) * 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Modele animal non humain de sarcome

Also Published As

Publication number Publication date
EP2124910A4 (fr) 2012-02-15
AU2007341977B2 (en) 2013-05-23
WO2008083326A2 (fr) 2008-07-10
AU2007341977A1 (en) 2008-07-10
WO2008083326A3 (fr) 2008-11-13
EP2687206B1 (fr) 2017-12-13
CA2711003A1 (fr) 2008-07-10
EP2124910A2 (fr) 2009-12-02
CA2711003C (fr) 2017-02-21
EP2687206A1 (fr) 2014-01-22

Similar Documents

Publication Publication Date Title
CA2711003C (fr) Therapie antitumorale par ciblage de ews-fli1
US9758481B2 (en) Targeting of EWS-FLI1 as anti-tumor therapy
AU2017201507B2 (en) Methods and compositions for treating Ewing's sarcoma family of tumors
JP6389884B2 (ja) 癌を治療するための方法及び組成物
JP2002511852A (ja) 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
CN108976172B (zh) 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
Song et al. Discovery of bazedoxifene analogues targeting glycoprotein 130
Wan et al. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors
Liu et al. Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with anti-tumor activities in multiple tumor lines
Meyer The Design, Synthesis, and Investigation into Small Molecule Modulators of the Src Homology 2 Domain-Containing Inositol 5’-Phosphatase (SHIP)
WO2023119334A1 (fr) Composé anticancéreux par combinaison d'une molécule de ponatinib avec une molécule inhibitrice de hdac utilisant un lieur à longueur variable
Tosso Design and synthesis of small molecule disruptors of EWS-FLI1 in Ewing's sarcoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170106

FZDE Dead

Effective date: 20190919